GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Price & Overview

NYSE:DNA • US37611X2099

Current stock price

6.64 USD
-0.19 (-2.78%)
Last:

The current stock price of DNA is 6.64 USD. Today DNA is down by -2.78%. In the past month the price decreased by -24.11%. In the past year, price decreased by -6.05%.

DNA Key Statistics

52-Week Range5 - 17.58
Current DNA stock price positioned within its 52-week range.
1-Month Range6.26 - 9.72
Current DNA stock price positioned within its 1-month range.
Market Cap
391.229M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-5.64
Dividend Yield
N/A

DNA Stock Performance

Today
-2.78%
1 Week
+7.73%
1 Month
-24.11%
3 Months
-15.68%
Longer-term
6 Months -39.93%
1 Year -6.05%
2 Years -85.28%
3 Years -87.16%
5 Years N/A
10 Years N/A

DNA Stock Chart

GINKGO BIOWORKS HOLDINGS INC / DNA Daily stock chart

DNA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to DNA. When comparing the yearly performance of all stocks, DNA is a bad performer in the overall market: 78.12% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DNA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to DNA. DNA has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DNA Earnings

On February 26, 2026 DNA reported an EPS of -1.41 and a revenue of 33.40M. The company beat EPS expectations (4.05% surprise) and missed revenue expectations (-10.85% surprise).

Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.41
Revenue Reported33.396M
EPS Surprise 4.05%
Revenue Surprise -10.85%

DNA Forecast & Estimates

11 analysts have analysed DNA and the average price target is 10.2 USD. This implies a price increase of 53.61% is expected in the next year compared to the current price of 6.64.

For the next year, analysts expect an EPS growth of 28.19% and a revenue growth -1.61% for DNA


Analysts
Analysts41.82
Price Target10.2 (53.61%)
EPS Next Y28.19%
Revenue Next Year-1.61%

DNA Groups

Sector & Classification

DNA Financial Highlights

Over the last trailing twelve months DNA reported a non-GAAP Earnings per Share(EPS) of -5.64. The EPS increased by 36.91% compared to the year before.


Income Statements
Revenue(TTM)170.16M
Net Income(TTM)-312.76M
Industry RankSector Rank
PM (TTM) N/A
ROA -27.93%
ROE -61.5%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%29.5%
Sales Q2Q%-23.84%
EPS 1Y (TTM)36.91%
Revenue 1Y (TTM)-25.06%

DNA Ownership

Ownership
Inst Owners64.86%
Shares58.92M
Float47.65M
Ins Owners3.32%
Short Float %15.71%
Short Ratio6.58

About DNA

Company Profile

DNA logo image Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 485 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

Company Info

IPO: 2021-04-19

GINKGO BIOWORKS HOLDINGS INC

27 Drydock Avenue, 8th Floor

Boston MASSACHUSETTS US

CEO: Harry E. Sloan

Employees: 834

DNA Company Website

DNA Investor Relations

Phone: 18774425362

GINKGO BIOWORKS HOLDINGS INC / DNA FAQ

What does GINKGO BIOWORKS HOLDINGS INC do?

Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 485 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.


What is the current price of DNA stock?

The current stock price of DNA is 6.64 USD. The price decreased by -2.78% in the last trading session.


Does GINKGO BIOWORKS HOLDINGS INC pay dividends?

DNA does not pay a dividend.


What is the ChartMill technical and fundamental rating of DNA stock?

DNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Should I buy DNA stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DNA.


What is GINKGO BIOWORKS HOLDINGS INC worth?

GINKGO BIOWORKS HOLDINGS INC (DNA) has a market capitalization of 391.23M USD. This makes DNA a Small Cap stock.


Who owns GINKGO BIOWORKS HOLDINGS INC?

You can find the ownership structure of GINKGO BIOWORKS HOLDINGS INC (DNA) on the Ownership tab.